Last reviewed · How we verify

Tislelizumab and nintedanib

The Affiliated Hospital of Qingdao University · FDA-approved active Small molecule

Tislelizumab and nintedanib is a PD-1 inhibitor + tyrosine kinase inhibitor combination Small molecule drug developed by The Affiliated Hospital of Qingdao University. It is currently FDA-approved for Non-small cell lung cancer (NSCLC) with specific molecular or histological subtypes.

Tislelizumab blocks PD-1 to enhance anti-tumor immunity, while nintedanib inhibits multiple receptor tyrosine kinases to reduce angiogenesis and fibrosis.

Tislelizumab blocks PD-1 to enhance anti-tumor immunity, while nintedanib inhibits multiple receptor tyrosine kinases to reduce angiogenesis and fibrosis. Used for Non-small cell lung cancer (NSCLC) with specific molecular or histological subtypes.

At a glance

Generic nameTislelizumab and nintedanib
SponsorThe Affiliated Hospital of Qingdao University
Drug classPD-1 inhibitor + tyrosine kinase inhibitor combination
TargetPD-1 (tislelizumab); VEGFR, FGFR, PDGFR (nintedanib)
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Tislelizumab is a humanized anti-PD-1 monoclonal antibody that restores T-cell-mediated immune responses against cancer cells. Nintedanib is a small-molecule tyrosine kinase inhibitor targeting VEGFR, FGFR, and PDGFR, which suppresses tumor angiogenesis and fibroblast-mediated stromal remodeling. The combination aims to synergize immunotherapy with anti-angiogenic and anti-fibrotic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tislelizumab and nintedanib

What is Tislelizumab and nintedanib?

Tislelizumab and nintedanib is a PD-1 inhibitor + tyrosine kinase inhibitor combination drug developed by The Affiliated Hospital of Qingdao University, indicated for Non-small cell lung cancer (NSCLC) with specific molecular or histological subtypes.

How does Tislelizumab and nintedanib work?

Tislelizumab blocks PD-1 to enhance anti-tumor immunity, while nintedanib inhibits multiple receptor tyrosine kinases to reduce angiogenesis and fibrosis.

What is Tislelizumab and nintedanib used for?

Tislelizumab and nintedanib is indicated for Non-small cell lung cancer (NSCLC) with specific molecular or histological subtypes.

Who makes Tislelizumab and nintedanib?

Tislelizumab and nintedanib is developed and marketed by The Affiliated Hospital of Qingdao University (see full The Affiliated Hospital of Qingdao University pipeline at /company/the-affiliated-hospital-of-qingdao-university).

What drug class is Tislelizumab and nintedanib in?

Tislelizumab and nintedanib belongs to the PD-1 inhibitor + tyrosine kinase inhibitor combination class. See all PD-1 inhibitor + tyrosine kinase inhibitor combination drugs at /class/pd-1-inhibitor-tyrosine-kinase-inhibitor-combination.

What development phase is Tislelizumab and nintedanib in?

Tislelizumab and nintedanib is FDA-approved (marketed).

What are the side effects of Tislelizumab and nintedanib?

Common side effects of Tislelizumab and nintedanib include Fatigue, Diarrhea, Nausea, Decreased appetite, Immune-related adverse events (e.g., pneumonitis, hepatitis).

What does Tislelizumab and nintedanib target?

Tislelizumab and nintedanib targets PD-1 (tislelizumab); VEGFR, FGFR, PDGFR (nintedanib) and is a PD-1 inhibitor + tyrosine kinase inhibitor combination.

Related